GABAergic signaling as therapeutic target for autism spectrum disorders

Frontiers in Pediatrics

Volumn 2, Issue JUL, 2014, Pages

  Cellot, Giada ^a   Cherubini, Enrico ^a,b  

^a SISSA   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

Author keywords

Autism spectrum disorders; Bumetanide; Excitatory inhibitory balance; GABA receptors; Neuro developmental disorders

Indexed keywords

EID: 84922677627     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2014.00070     Document Type: Review

References (125)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Association (2000)
2. Levy SE, Mandell DS, Schultz R. Autism. Lancet (2009) 374:1627-38. doi: 10.1016/S0140-6736(09)61376-3
3. Ben-Ari Y, Woodin MA, Sernagor E, Cancedda L, Vinay L, Rivera C, et al. Refuting the challenges of the developmental shift of polarity of GABA actions: GABA more exciting than ever! Front Cell Neurosci (2012) 6:35. doi:10.3389/fncel.2012.00035
4. Frye RE, Rossignol D, Casanova MF, Brown GL, Martin V, Edelson S, et al. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front Public Health (2013) 1:31. doi:10.3389/fpubh.2013.00031
5. Valeeva G, Abdullin A, Tyzio R, Skorinkin A, Nikolski E, Ben-Ari Y, et al. Temporal coding at the immature depolarizing GABAergic synapse. Front Cell Neurosci (2010) 14:4. doi:10.3389/fncel.2010.00017
6. Ben-Ari Y, Cherubini E, Corradetti R, Gaiarsa JL. Giant synaptic potentials in immature rat CA3 hippocampal neurones. J Physiol (1989) 416:303-25
7. Cherubini E, Gaiarsa JL, Ben-Ari Y. Review GABA: an excitatory transmitter in early postnatal life. Trends Neurosci (1991) 14:515-9. doi:10.1016/0166-2236(91)90003-D
8. Rivera C, Voipio J, Payne JA, Ruusuvuori E, Lahtinen H, Lamsa K, et al. The K+/Cl-co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature (1999) 397:251-5. doi:10.1038/16697
9. Yamada J, Okabe A, Toyoda H, Kilb W, Luhmann HJ, Fukuda A. Cl-uptake promoting depolarizing GABA actions in immature rat neocortical neurones is mediated by NKCC1. J Physiol (2004) 557:829-41. doi:10.1113/jphysiol.2004.062471
10. Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, Benke TA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med (2005) 11:1205-13. doi:10.1038/nm1301
11. Wang DD, Kriegstein AR. Defining the role of GABA in cortical development. J Physiol (2009) 587:1873-9. doi:10.1113/jphysiol.2008.167635
12. Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R. GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev (2007) 87:1215-84. doi:10.1152/physrev.00017.2006
13. Cherubini E, Griguoli M, Safiulina V, Lagostena L. The depolarizing action of GABA controls early network activity in the developing hippocampus. Mol Neurobiol (2011) 43:97-106. doi:10.1007/s12035-010-8147-z
14. Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast (2011) 2011:297153. doi:10.1155/2011/297153
15. Tyzio R, Represa A, Jorquera I, Ben-Ari Y, Gozlan H, Aniksztejn L. The establishment of GABAergic and glutamatergic synapses on CA1 pyramidal neurons is sequential and correlates with the development of the apical dendrite. J Neurosci (1999) 19:10372-82
16. Behar TN, Schaffner AE, Scott CA, O'Connell C, Barker JL. Differential response of cortical plate and ventricular zone cells to GABA as a migration stimulus. J Neurosci (1998) 18:6378-87
17. Nguyen L, Rigo JM, Rocher V, Belachew S, Malgrange B, Rogister B, et al. Neurotransmitters as early signals for central nervous system development. Cell Tissue Res (2001) 305:187-202. doi:10.1007/s004410000343
18. Demarque M, Represa A, Becq H, Khalilov I, Ben-Ari Y, Aniksztejn L. Paracrine intercellular communication by a Ca2+-and SNARE-independent release of GABA and glutamate prior to synapse formation. Neuron (2002) 36:1051-61. doi:10.1016/S0896-6273(02)01053-X
19. Manent JB, Demarque M, Jorquera I, Pellegrino C, Ben-Ari Y, Aniksztejn L, et al. A noncanonical release of GABA and glutamate modulates neuronal migration. J Neurosci (2005) 25:4755-65. doi:10.1523/JNEUROSCI.0553-05.2005
20. Cancedda L, Fiumelli H, Chen K, Poo MM. Excitatory GABA action is essential for morphological maturation of cortical neurons in vivo. J Neurosci (2007) 27:5224-35. doi:10.1523/JNEUROSCI.5169-06.2007
21. Leinekugel X, Khazipov R, Cannon R, Hirase H, Ben-Ari Y, Buzsáki G. Correlated bursts of activity in the neonatal hippocampus in vivo. Science (2002) 296:2049-52. doi:10.1126/science.1071111
22. Stockard-Pope J, Werner SS, Bickford RG. Atlas of Neonatal Electroencephalography. New York, NY: Raven Press (1992)
23. De la Prida LM, Huberfeld G, Cohen I, Miles R. Threshold behavior in the initiation of hippocampal population bursts. Neuron (2006) 49:131-42. doi:10.1016/j.neuron.2005.10.034
24. De la Prida L, Sanchez-Andres JV. Heterogeneous populations of cells mediate spontaneous synchronous bursting in the developing hippocampus through a frequency-dependent mechanism. Neuroscience (2000) 97:227-41. doi:10.1016/S0306-4522(00)00029-4
25. Safiulina VF, Zacchi P, Taglialatela M, Yaari Y, Cherubini E. Low expression of Kv7/M channels facilitates intrinsic and network bursting in the developing rat hippocampus. J Physiol (2008) 586:5437-53. doi:10.1113/jphysiol.2008.156257
26. Sipilä ST, Huttu K, Soltesz I, Voipio J, Kaila K. Depolarizing GABA acts on intrinsically bursting pyramidal neurons to drive giant depolarizing potentials in the immature hippocampus. J Neurosci (2005) 25:5280-9. doi:10.1523/JNEUROSCI.0378-05.2005
27. Sipilä ST, Huttu K, Voipio J, Kaila K. Intrinsic bursting of immature CA3 pyramidal neurons and consequent giant depolarizing potentials are driven by a persistent Na+ current and terminated by a slow Ca2+-activated K+ current. Eur J Neurosci (2006) 23:2330-8. doi:10.1111/j.1460-9568.2006.04757.x
28. Marchionni I, Omrani A, Cherubini E. In the developing rat hippocampus a tonic GABAA-mediated conductance selectively enhances the glutamatergic drive of principal cells. J Physiol (2007) 581:515-28. doi:10.1113/jphysiol.2006.125609
29. Yue C, Yaari Y. KCNQ/M channels control spike after depolarization and burst generation in hippocampal neurons. J Neurosci (2004) 24:4614-24. doi:10.1523/JNEUROSCI.0765-04.2004
30. Kasyanov AM, Safiulina VF, Voronin LL, Cherubini E. GABA-mediated giant depolarizing potentials as coincidence detectors for enhancing synaptic efficacy in the developing hippocampus. Proc Natl Acad Sci U S A (2004) 101:3967-72. doi:10.1073/pnas.0305974101
31. Mohajerani MH, Sivakumaran S, Zacchi P, Aguilera P, Cherubini E. Correlated network activity enhances synaptic efficacy via BDNF and the ERK pathway at immature CA3 CA1 connections in the hippocampus. Proc Natl Acad Sci U S A (2007) 104:13176-81. doi:10.1073/pnas.0704533104
32. Freund TF, Buzsáki G. Interneurons of the hippocampus. Hippocampus (1996) 6:347-470. doi:10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I
33. Komuro H, Rakic P. Orchestration of neuronal migration by activity of ion channels, neurotransmitter receptors, and intracellular Ca2+ fluctuations. J Neurobiol (1998) 37:110-30. doi:10.1002/(SICI)1097-4695(199810)37:1<110::AID-NEU9>3.3.CO;2-Q
34. Spitzer NC. Activity-dependent neuronal differentiation prior to synapse formation: the functions of calcium transients. J Physiol Paris (2002) 96:73-80. doi:10.1016/S0928-4257(01)00082-1
35. Klausberger T, Somogyi P. Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. Science (2008) 321:53-7. doi:10.1126/science.1149381
36. Cook EH, Courchesne RY, Cox NJ, Lord C, Gonen D, Guter SJ, et al. Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. Am J Hum Genet (1998) 62:1077-83. doi:10.1086/301832
37. Shao Y, Cuccaro ML, Hauser ER, Raiford KL, Menold MM, Wolpert CM, et al. Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. Am J Hum Genet (2003) 72:539-48. doi:10.1086/367846
38. Xu X, Wells AB, O'Brien DR, Nehorai A, Dougherty JD. Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders. J Neurosci (2014) 34:1420-31. doi:10.1523/JNEUROSCI.4488-13.2014
39. Oblak A, Gibbs TT, Blatt GJ. Decreased GABAA receptors and benzodiazepine binding sites in the anterior cingulate cortex in autism. Autism Res (2009) 2:205-19. doi:10.1002/aur.88
40. Oblak A, Gibbs T, Blatt GJ. Decreased GABAB receptors in the cingulated cortex and fusiform gyrus in autism. J Neurochem (2010) 114:1414-23. doi:10.1111/j.1471-4159.2010.06858.x
41. Guptill JT, Booker AB, Gibbs TT, Kemper TL, Bauman ML, Blatt GJ. [3H]-flunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: a multiple concentration autoradiographic study. J Autism Dev Disord (2007) 37:911-20. doi:10.1007/s10803-006-0226-7
42. Whitney ER, Kemper TL, Bauman ML, Rosene DL, Blatt GJ. Cerebellar Purkinje cells are reduced in a subpopulation of autistic brains: a stereological experiment using calbindin-D28k. Cerebellum (2008) 7:406-16. doi:10.1007/s12311-008-0043-y
43. Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry (2002) 52:805-10. doi:10.1016/S0006-3223(02)01430-0
44. Yip J, Soghomonian JJ, Blatt GJ. Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: pathophysiological implications. Acta Neuropathol (2007) 113:559-68. doi:10.1007/s00401-006-0176-3
45. Yip J, Soghomonian JJ, Blatt GJ. Decreased GAD65 mRNA levels in select subpopulations of neurons in the cerebellar dentate nuclei in autism: an in situ hybridization study. Autism Res (2009) 2:50-9. doi:10.1002/aur.62
46. Lawrence YL, Kemper TL, Bauman ML, Blatt GJ. Parvalbumin, calbindin, and calretinin immunoreactive interneuron density in autism. Acta Neurol Scand (2010) 121:99-108. doi:10.1111/j.1600-0404.2009.01234.x
47. Casanova MF, Buxhoeveden DP, Gomez J. Disruption of the inhibitory architecture of the cell minicolumn: implications for autism. Neuroscientist (2003) 9:496-507. doi:10.1177/1073858403253552
48. Harada M, Taki MM, Nose A, Kubo H, Mori K, Nishitani H, et al. Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 Tesla instrument. J Autism Dev Disord (2011) 41:447-54. doi:10.1007/s10803-010-1065-0
49. Rojas DC, Singel D, Steinmetz S, Hepburn S, Brown MS. Decreased left perisylvian GABA concentration in children with autism and unaffected siblings. Neuroimage (2014) 86:28-34. doi:10.1016/j.neuroimage.2013.01.045
50. Mori T, Mori K, Fujii E, Toda Y, Miyazaki M, Harada M, et al. Evaluation of the GABAergic nervous system in autistic brain: (123)I-iomazenil SPECT study. Brain Dev (2012) 34:648-54. doi:10.1016/j.braindev.2011.10.007
51. Yamashita Y, Matsuishi T, Ishibashi M, Kimura A, Onishi Y, Yonekura Y, et al. Decrease in benzodiazepine receptor binding in the brains of adult patients with Rett syndrome. J Neurol Sci (1998) 154:146-50. doi:10.1016/S0022-510X(97)00223-2
52. Mendez MA, Horder J, Myers J, Coghlan S, Stokes P, Erritzoe D, et al. The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology (2013) 68:195-201. doi:10.1016/j.neuropharm.2012.04.008
53. Duarte ST, Armstrong J, Roche A, Ortez C, Pérez A, O'Callaghan Mdel M, et al. Abnormal expression of cerebrospinal fluid cation chloride cotransporters in patients with Rett syndrome. PLoS One (2013) 8:e68851. doi:10.1371/journal.pone.0068851
54. Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev (2012) 36:2044-55. doi:10.1016/j.neubiorev.2012.07.005
55. Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, Bauman ML. Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J Autism Dev Disord (2001) 31:537-43. doi:10.1023/A:1013238809666
56. Williams RS, Hauser SL, Purpura DP, DeLong GR, Swisher CN. Autism and mental retardation: neuropathologic studies performed in four retarded persons with autistic behavior. Arch Neurol (1980) 37:749-53. doi:10.1001/archneur.1980.00500610029003
57. Bauman ML, Kemper TL. Histoanatomic observations of the brain in early infantile autism. Neurology (1985) 35:866-74. doi:10.1212/WNL.35.6.866
58. Yip J, Soghomonian JJ, Blatt GJ. Increased GAD67 mRNA levels in cerebellar interneurons in autism: implications for Purkinje cell dysfunction. J Neurosci Res (2008) 86:525-30. doi:10.1002/jnr.21520
59. Casanova MF, Buxhoeveden DP, Switala AE, Roy E. Minicolumnar pathology in autism. Neurology (2002) 58:428-32. doi:10.1212/WNL.58.3.428
60. Casanova MF, Buxhoeveden DP, Switala AE, Roy E. Asperger's syndrome and cortical neuropathology. J Child Neurol (2002) 17:142-5. doi:10.1177/088307380201700211
61. Sun L, Grützner C, Bölte S, Wibral M, Tozman T, Schlitt S, et al. Impaired gamma-band activity during perceptual organization in adults with autism spectrum disorders: evidence for dysfunctional network activity in frontal-posterior cortices. J Neurosci (2012) 32:9563-73. doi:10.1523/JNEUROSCI.1073-12.2012
62. Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature (2009) 459:698-702. doi:10.1038/nature07991
63. Uhlhaas PJ, Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron (2006) 52:155-68. doi:10.1016/j.neuron.2006.09.020
64. Meador KJ, Loring DW. Risks of in utero exposure to valproate. JAMA (2013) 309(16):1730-1. doi:10.1001/jama.2013.4001
65. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of Fragile X syndrome. J Neurosci (2010) 30:9929-38. doi:10.1523/JNEUROSCI.1714-10.2010
66. Selby L, Zhang C, Sun QQ. Major defects in neocortical GABAergic inhibitory circuits in mice lacking the Fragile X mental retardation protein. Neurosci Lett (2007) 412:227-32. doi:10.1016/j.neulet.2006.11.062
67. Gibson JR, Bartley AF, Hays SA, Huber KM. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of Fragile X syndrome. J Neurophysiol (2008) 100:2615-26. doi:10.1152/jn.90752.2008
68. Gantois I, Vandesompele J, Speleman F, Reyniers E, D'Hooge R, Severijnen LA, et al. Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the Fragile X knockout mouse model. Neurobiol Dis (2006) 21:346-57. doi:10.1016/j.nbd.2005.07.017
69. Curia G, Papouin T, Séguéla P, Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of Fragile X syndrome. Cereb Cortex (2009) 19:1515-20. doi:10.1093/cercor/bhn159
70. Tyzio R, Nardou R, Ferrari DC, Tsintsadze T, Shahrokhi A, Eftekhari S, et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science (2014) 343:675-9. doi:10.1126/science.1247190
71. Dani VS, Chang Q, Maffei A, Turrigiano GG, Jaenisch R, Nelson SB. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A (2005) 102:12560-5. doi:10.1073/pnas.0506071102
72. Medrihan L, Tantalaki E, Aramuni G, Sargsyan V, Dudanova I, Missler M, et al. Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J Neurophysiol (2008) 99:112-21. doi:10.1152/jn.00826.2007
73. Jin X, Cui N, Zhong W, Jin XT, Jiang C. GABAergic synaptic inputs of locus coeruleus neurons in wild-type and Mecp2-null mice. Am J Physiol Cell Physiol (2013) 304:844-57. doi:10.1152/ajpcell.00399.2012
74. Zhang L, He J, Jugloff DG, Eubanks JH. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus (2008) 18:294-309. doi:10.1002/hipo.20389
75. Chao HT, Chen H, Samaco RC, Xue M, Chahrour M, Yoo J, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature (2010) 468:263-9. doi:10.1038/nature09582
76. Egawa K, Kitagawa K, Inoue K, Takayama M, Takayama C, Saitoh S, et al. Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome. Sci Transl Med (2012) 4:163ra157. doi:10.1126/scitranslmed.3004655
77. Sinkkonen ST, Homanics GE, Korpi ER. Mouse models of Angelman syndrome, a neurodevelopmental disorder, display different brain regional GABA(A) receptor alterations. Neurosci Lett (2003) 340:205-8. doi:10.1016/S0304-3940(03)00123-X
78. Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB, et al. Autistic-like behaviour in Scn1a+/-mice and rescue by enhanced GABA-mediated neurotransmission. Nature (2012) 489:385-90. doi:10.1038/nature11356
79. Tabuchi K, Blundell J, Etherton MR, Hammer RE, Liu X, Powell CM, et al. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science (2007) 318:71-6. doi:10.1126/science.1146221
80. Földy C, Malenka RC, Südhof TC. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron (2013) 78:498-509. doi:10.1016/j.neuron.2013.02.036
81. Cellot G, Cherubini E. Reduced inhibitory gate in the barrel cortex of neuroligin3 R451C knock-in mice, an animal model of autism spectrum disorders. Physiol Rep (2014) 2:e12070. doi:10.14814/phy2.12077
82. Gogolla N, Leblanc JJ, Quast KB, Südhof TC, Fagiolini M, Hensch TK. Common circuit defect of excitatory-inhibitory balance in mouse models of autism. J Neurodev Disord (2009) 1:172-81. doi:10.1007/s11689-009-9023-x
83. Sgadò P, Genovesi S, Kalinovsky A, Zunino G, Macchi F, Allegra M, et al. Loss of GABAergic neurons in the hippocampus and cerebral cortex of engrailed-2 null mutant mice: implications for autism spectrum disorders. Exp Neurol (2013) 247:496-505. doi:10.1016/j.expneurol.2013.01.021
84. Banerjee A, García-Oscos F, Roychowdhury S, Galindo LC, Hall S, Kilgard MP, et al. Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. Int J Neuropsychopharmacol (2013) 16:1309-18. doi:10.1017/S1461145712001216
85. Oostra BA, Chiurazzi P. The Fragile X gene and its function. Clin Genet (2001) 60:399-408. doi:10.1034/j.1399-0004.2001.600601.x
86. Paluszkiewicz SM, Martin BS, Huntsman MM. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci (2011) 33:349-64. doi:10.1159/000329420
87. Gonçalves JT, Anstey JE, Golshani P, Portera-Cailliau C. Circuit level defects in the developing neocortex of Fragile X mice. Nat Neurosci (2013) 16:903-9. doi:10.1038/nn.3415
88. Zhang L, Alger BE. Enhanced endocannabinoid signaling elevates neuronal excitability in Fragile X syndrome. J Neurosci (2010) 30:5724-9. doi:10.1523/JNEUROSCI.0795-10.2010
89. D'Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, et al. Expression of the GABAergic system in animal models for Fragile X syndrome and Fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res (2009) 1253:176-83. doi:10.1016/j.brainres.2008.11.075
90. Centonze D, Rossi S, Mercaldo V, Napoli I, Ciotti MT, De Chiara V, et al. Abnormal striatal GABA transmission in the mouse model for the Fragile X syndrome. Biol Psychiatry (2008) 63:963-73. doi:10.1016/j.biopsych.2007.09.008
91. Tyzio R, Cossart R, Khalilov I, Minlebaev M, Hübner CA, Represa A, et al. Maternal oxytocin triggers a transient inhibitory switch in GABA signaling in the fetal brain during delivery. Science (2006) 314:1788-92. doi:10.1126/science.1133212
92. Akbarian S, Chen RZ, Gribnau J, Rasmussen TP, Fong H, Jaenisch R, et al. Expression pattern of the Rett syndrome gene MeCP2 in primate prefrontal cortex. Neurobiol Dis (2001) 8:784-91. doi:10.1006/nbdi.2001.0420
93. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet (1999) 23:185-8. doi:10.1038/13810
94. Zhang ZW, Zak JD, Liu H. MeCP2 is required for normal development of GABAergic circuits in the thalamus. J Neurophysiol (2010) 103:2470-81. doi:10.1152/jn.00601.2009
95. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet (2008) 372:657-68. doi:10.1016/S0140-6736(08)61279-9
96. Talos DM, Sun H, Kosaras B, Joseph A, Folkerth RD, Poduri A, et al. Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. Ann Neurol (2012) 71:539-51. doi:10.1002/ana.22696
97. Jamain S, Quach H, Betancur C, Råstam M, Colineaux C, Gillberg IC, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet (2003) 34:27-9. doi:10.1038/ng1136
98. Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature (2008) 455:903-11. doi:10.1038/nature07456
99. Etherton M, Földy C, Sharma M, Tabuchi K, Liu X, Shamloo M, et al. Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. Proc Natl Acad Sci U S A (2011) 108:13764-9. doi:10.1073/pnas.1111093108
100. Pizzarelli R, Cherubini E. Developmental regulation of GABAergic signalling in the hippocampus of neuroligin 3 R451C knock-in mice: an animal model of autism. Front Cell Neurosci (2013) 4(7):85. doi:10.3389/fncel.2013.00085
101. Cheh MA, Millonig JH, Roselli LM, Ming X, Jacobsen E, Kamdar S, et al. En2 knockout mice display neurobehavioral and neurochemical alterations relevant to autism spectrum disorder. Brain Res (2006) 1116:166-76. doi:10.1016/j.brainres.2006.07.086
102. Sudarov A, Joyner AL. Cerebellum morphogenesis: the foliation pattern is orchestrated by multi-cellular anchoring centers. Neural Dev (2007) 3(2):26. doi:10.1186/1749-8104-2-26
103. Tripathi PP, Sgadò P, Scali M, Viaggi C, Casarosa S, Simon HH, et al. Increased susceptibility to kainic acid-induced seizures in engrailed-2 knockout mice. Neuroscience (2009) 159:842-9. doi:10.1016/j.neuroscience.2009.01.007
104. Wagner GC, Reuhl KR, Cheh M, McRae P, Halladay AK. A new neurobehavioral model of autism in mice: pre-and postnatal exposure to sodium valproate. J Autism Dev Disord (2006) 36:779-93. doi:10.1007/s10803-006-0117-y
105. Cherubini E. Phasic GABAA-Mediated Inhibition: Jasper's Basic Mechanisms of the Epilepsies. Bethesda, MD: National Center for Biotechnology Information (2012)
106. Kneussel M, Betz H. Receptors, gephyrin and gephyrin-associated proteins: novel insights into the assembly of inhibitory postsynaptic membrane specializations. J Physiol (2000) 1:1-9. doi:10.1111/j.1469-7793.2000.t01-4-00001.x
107. Buddhala C, Hsu CC, Wu JY. A novel mechanism for GABA synthesis and packaging into synaptic vesicles. Neurochem Int (2009) 55:9-12. doi:10.1016/j.neuint.2009.01.020
108. Di Martino A, Tuchman RF. Antiepileptic drugs: affective use in autism spectrum disorders. Pediatr Neurol (2001) 25:199-207. doi:10.1016/S0887-8994(01)00276-4
109. Jambaqué I, Chiron C, Dumas C, Mumford J, Dulac O. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res (2000) 38:151-60. doi:10.1016/S0920-1211(99)00082-0
110. Han S, Tai C, Jones CJ, Scheuer T, Catterall WA. Enhancement of inhibitory neurotransmission by GABAA receptors having a2,3-subunits ameliorates behavioral deficits in a mouse model of autism. Neuron (2014) 81:1282-9. doi:10.1016/j.neuron.2014.01.016
111. Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, Pozzo-Miller L, et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech (2012) 5:733-45. doi:10.1242/dmm.011007
112. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science (2007) 315:1143-7. doi:10.1126/science.1138389
113. Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci U S A (2007) 104:1931-6. doi:10.1073/pnas.0610593104
114. Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A (2009) 106:2029-34. doi:10.1073/pnas.0812394106
115. Kline DD, Ogier M, Kunze DL, Katz DM. Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. J Neurosci (2010) 30:5303-10. doi:10.1523/JNEUROSCI.5503-09.2010
116. Olmos-Serrano JL, Corbin JG, Burns MP. The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of Fragile X syndrome. Dev Neurosci (2011) 33:395-403. doi:10.1159/000332884
117. Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics (2010) 7:264-74. doi:10.1016/j.nurt.2010.05.005
118. Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol (2012) 4:a009886. doi:10.1101/cshperspect.a009886
119. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with Fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med (2012) 4:152ra127. doi:10.1126/scitranslmed.3004214
120. Oberman LM. mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders. Expert Opin Investig Drugs (2012) 21(12):1819-25. doi:10.1517/13543784.2012.729819
121. Marrosu F, Marrosu G, Rachel MG, Biggio G. Paradoxical reactions elicited by diazepam in children with classic autism. Funct Neurol (1987) 2:355-61
122. Hochman DW. The extracellular space and epileptic activity in the adult brain: explaining the antiepileptic effects of furosemide and bumetanide. Epilepsia (2012) 1:18-25. doi:10.1111/j.1528-1167.2012.03471.x
123. Lemonnier E, Ben-Ari Y. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr (2010) 99:1885-8. doi:10.1111/j.1651-2227.2010.01933.x
124. Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry (2012) 2:e202. doi:10.1038/tp.2012.124
125. Hadjikhani N, Zürcher NR, Rogier O, Ruest T, Hippolyte L, Ben-Ari Y, et al. Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study. Autism (2013). doi:10.1177/1362361313514141